Social Media Ideas for Biib

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

Ipca inks licensing agreement with Bhami Research for biologics delivery platform access

Licencing agreement grants Ipca access to Bhami Research’s proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialisation of mult...

AAIC: Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline

Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharma’s decision to race the molecule into p...

<![CDATA[Biogen Enters $1 Billion Agreement to Acquire RayThera Inc. ]]>

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Biogen inks $1B RayThera buyout to bag preclinical immunology assets

Biogen has struck a backloaded, $1 billion deal to buy RayThera, snagging a pipeline of anti-inflammatory drug candidates led by a prospect on the cusp of clinical development.

Boehringer Ingelheim Launches Discovery Collaboration with Immunai to Identify Novel T-Cell Targets Across Oncology and...

Immunai, a leading AI biotech company specialized in mapping the human immune system, today announced a multi-project collaboration and an initial discovery program with Boehringe...

Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg...

AbbVie to Acquire Apogee Therapeutics for $10.9B

Apogee’s lead candidate zumilokibart, an IL-13 inhibitor also called APG777, is a long-acting treatment that, according to the company, holds “pipeline-in-a-product potential” beca...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik]]>

INVIVYD

INVIVYD Anonymous (not verified) Thu, 07/02/2026 - 06:06 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...

<![CDATA[Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand St...

Biogen adds more immune drugs in $1B buyout of secretive startup RayThera

The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues. 

Gilead: 'Hold' On Biktarvy Sales Growth And MM Drug Development Program

Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs

The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.

<![CDATA[FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease]]>

ABIVAX Société Anonyme (ABVX) Discusses Positive Phase III ABTECT Trial Results for Obefazimod in Ulcerative Colitis - S...

Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Bruk...

Absci Corporation: A Big Binary Approaching In Alopecia